Market Cap: $1.14B
SI
Savara Inc.
SVRA
NASDAQ (NASDAQ Global Select)USD
Market Cap: $1.14B
Savara (Ticker: SVRA) has made significant strides with its drug candidate MOLBREEVI, as the U.S. Food and Drug Administration (FDA) accepts the biologics license application for this innovative treat…
Savara Pharmaceuticals, a company focused on developing therapies for rare respiratory diseases, announces that the FDA has extended the Priority Review of its Biologics License Application (BLA) for…
Savara's Position in the Evolving Landscape of Respiratory Therapeutics Savara, a company specializing in the development of novel therapies for respiratory diseases, is well-positioned to capitalize…
Savara Advances in Respiratory Therapeutics Amidst Market Optimism Savara, a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases, continues to…
Savara Faces Class Action Lawsuit Over Alleged Securities Fraud Savara Inc., a biopharmaceutical company focused on developing treatments for rare respiratory diseases, is embroiled in a class action…
Savara Faces Class Action Lawsuits Over Misleading Statements on MOLBREEVI Savara Inc. is currently entangled in multiple class action lawsuits filed by the Schall Law Firm and the DJS Law Group, both…
### Savara Faces Class Action Lawsuits Over Misleading Statements Regarding FDA Approval Savara Inc. (NASDAQ: SVRA), a biotechnology firm specializing in the development of treatments for respiratory…
Savara Faces Class Action Lawsuits Over Misleading Statements Regarding MOLBREEVI Savara Inc. is currently embroiled in multiple class action lawsuits alleging that the company made false and misleadi…
Savara Inc. Faces Class Action Over Alleged Misrepresentation of Drug Application Savara Inc. is currently embroiled in multiple securities fraud class action lawsuits, which raise serious allegations…
Savara Faces Legal Challenges Over Biologics License Application Misstatements Savara Inc., a biotechnology company focused on developing treatments for rare lung diseases, finds itself under legal sc…
Savara Faces Class Action Lawsuits Over Biologics License Application Misstatements Savara Inc. is currently embroiled in multiple class action lawsuits accusing the company of violating federal secur…
Savara Faces Class Action Lawsuits Amid Allegations of Misleading Statements Savara Inc. (NASDAQ: SVRA) is currently embroiled in multiple class action lawsuits stemming from allegations that the comp…
Savara Faces Class Action Amid Allegations of Misleading Information on BLA Submission In a significant development for Savara Inc., the Law Offices of Howard G. Smith have announced a class action la…
Savara Faces Legal Scrutiny Over Allegations of Misleading Drug Approval Information Savara Inc., a biopharmaceutical company focused on developing treatments for pulmonary diseases, is currently unde…
Savara Faces Class Action Lawsuits Over Alleged Misleading Statements Regarding MOLBREEVI Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company focusing on rare respiratory diseases,…
Savara Faces Class Action Lawsuits Over Alleged Misrepresentations in Biologics License Application Savara Inc. is currently embroiled in multiple class action lawsuits, initiated by various law firms…
Savara Faces Class Action Lawsuits Over Alleged Misstatements Regarding MOLBREEVI Savara Inc., a biopharmaceutical company focused on developing treatments for rare respiratory diseases, finds itself…
Savara Faces Class Action Lawsuits Amid Regulatory Questions for MOLBREEVI Savara Inc., a clinical-stage biopharmaceutical company, is currently dealing with multiple class action lawsuits stemming fr…
Savara Faces Legal Scrutiny Over Alleged Misleading Statements on Drug Approval Process Savara Inc. is currently under investigation by national securities law firms Faruqi & Faruqi, LLP and Glancy Pr…
### Savara Faces Class Action Lawsuits Amidst Regulatory Challenges for MOLBREEVI Savara Inc., a clinical-stage biopharmaceutical company dedicated to developing treatments for rare respiratory diseas…
Savara Faces Class Action Lawsuit Over Biologics License Application Disclosure Issues Savara Inc., a biopharmaceutical company focused on developing treatments for rare lung diseases, is currently un…
Savara Faces Legal Challenges Over Biologics License Application Disclosures Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, currently finds itself under…
Savara Faces Class Action Lawsuit Over Alleged Securities Fraud Savara Inc. is currently embroiled in a class action lawsuit initiated by the Law Offices of Howard G. Smith, claiming securities fraud…
Savara Faces Class Action Lawsuit Over Allegations of Securities Fraud Savara Inc., a biopharmaceutical company focused on developing treatments for rare respiratory diseases, finds itself embroiled i…
Investors Mobilize Over Alleged Fraud in Savara’s Biologics License Application Process Recent developments indicate significant investor unrest surrounding Savara Inc. (NASDAQ: SVRA) due to allegatio…